[en] It establishes a method to categorize Nuclear Medicine Laboratories

[en] Background: This compound is a synthetic analogue of somatostatin by conjugating the Hydrazinocotinamide (Hynic) to Tyr³-Octreotide (Toc) radiolabeling via quelation with ^99mTc. Purpose: We have analyzed the feasibility in detecting neuroendocrine tumors (NET) by somatostatin receptor with ^99mTc Hynic-Toc. Methods: After comparative studies between ^99mTc Hynic-Toc and ¹¹¹In (pentetreotide) with excellent correlation, we have performed 48 scintigrams with ^99mTc Hynic-Toc. 35 patients with suspicions of NET were included (19 women, 16 men. Age range 22-75 y). We have performed planar images at 1,2,24 hs and tomographic images at 150 min after intravenous injection of 740 MBq ^99mTc Hynic-Toc. We compare the results with other diagnosis modalities and /or the histopathological findings after biopsy or surgery. Results: True Positive:17; True Negative:11; False Positive: 4; False Negative:3. Specificity=73.3%; Sensitivity=85%; Accuracy=80%; Not adverse effects were observed. Conclusions: ^99mTc Hynic-Toc is not limited availability of the isotope. It is a suitable radiopharmaceutical for in vivo evaluation to define tumor receptor status, staging, and for identification of patients who may benefit from therapy with somatostatin. The tumor uptake at 24 hs allows a better visualization of abdominal tumor sites. Tc Hynic-Toc is an alternative to ¹¹¹In-pentetreotide for imaging somatostatin receptor positive tumors. The study was offered to patients whom the scintigraphy with ¹¹¹In-pentetreotide offers a diagnosis alternative with high specificity and accessible cost

No abstract available

No abstract available

[en] The aim of this paper is to estimate the maximum therapeutic activity of ¹³¹I administered in DTC patients with iodine avid metastasis, treated by other tumors , or suffering from a different disease from DTC, following standard operating procedures (SOP) recommended by the European Nuclear Medicine Association (EANM), which gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of DTC such that the absorbed dose to the blood does not exceed 2 Gy (a widely accepted limit for bone marrow toxicity) and at 48 h after administration, the whole-body retention does not exceed 4.4 or 3 GBq in the absence or presence of iodine avid diffuse lung metastases respectively ( to avoid pneumonitis and pulmonary fibrosis risk). (author)